SmartClient 업그레이드

SmartClient에 대한 라이선스 요구 사항을 논의하여야 하는 경우, 당사의 Isomorphic Software 라이선스 전문가에게 문의하여 주시기 바랍니다.

일반 제공 가격은 하기와 같습니다. 할인된 가격을 확인하려면 로그인 하시기 바랍니다.

표시 생략 | 상세 내용 비표시 |
찾아보기:
통화:

SmartClient Upgrades and Support - Perpetual License

For customers with a perpetual license looking to upgrade their version of SmartClient to the latest version or in need of a technical support plan.

Please contact us for an upgrade quote.

  판매 가격 문의

SmartClient 라이센스

1 Software License is required per Developer.
Runtime Royalty Free.

SmartClient is available as a Perpetual License with no support or updates and as a Subscription License which includes product updates and technical support.

Subscription Licenses require a minimum commitment of 3 years and need to be renewed to continue using the software.

Licenses are offered and owned by project or company (for example a consultant cannot use a license to work for multiple customers. Licenses would need to be bought per customer).

Standard Support:

  • Access to the current documentation for the software.
  • Forum Support.
  • Email Support.
  • Guaranteed response within 72 business hours.
  • Limited incident support (up to 10 incidents per annum).
  • Roadmap Questions: the ability to ask if a given feature or capability is scheduled for the next release.
  • Eligible to receive emergency hotfix builds as may be provided.
  • Product fixes and new features. (Note: This does not apply to perpetual licenses, where new features and versions must be purchased separately)

Priority Unlimited Support
All the offerings from the Standard Support package plus:

  • 24/5 Worldwide Support.
  • Priority Support Handling - guaranteed response within 24 hours.
  • Prioritized Bug Review - Cases are immediately routed for priority assignment to a senior engineer.
  • Unlimited incident support.
  • Roadmap Influence: The ability to request that a feature be added to the roadmap for the next release or release after that.
  • Beta Program Privileges - Early access, priority enrollment, and extended trial periods for new product launches.